IMP-4 and OXA β-lactamases in Acinetobacter baumannii from Singapore

Journal of Antimicrobial Chemotherapy

Volumn 59, Issue 4, 2007, Pages 627-632

  Koh, Tse Hsien ^a   Sng, Li Hwei ^a   Wang, Grace Chee Yeng ^a   Hsu, Li Yang ^a,b   Zhao, Yi ^a  

^a SINGAPORE GENERAL HOSPITAL   (Singapore)

^b Dept Medicine Endocrinol Diabet   (Singapore)

Author keywords

Carbapenemase; Metallo b lactamase; Resistance

Indexed keywords

BACTERIAL DNA; BETA LACTAMASE; CARBAPENEMASE; CEFEPIME; IMIPENEM; LEVOFLOXACIN; MINOCYCLINE; PIPERACILLIN PLUS TAZOBACTAM; SULTAMICILLIN; TIGECYCLINE; UNCLASSIFIED DRUG; ANTIINFECTIVE AGENT; BACTERIAL PROTEIN; BETA LACTAMASE IMP 4; BETA-LACTAMASE IMP-4; CARBAPENEM DERIVATIVE;

ACINETOBACTER BAUMANNII; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL CHROMOSOME; BACTERIUM ISOLATE; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME ASSAY; GENETIC SCREENING; GENETIC VARIABILITY; HOSPITAL ADMISSION; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; NUCLEOTIDE SEQUENCE; POLYMERASE CHAIN REACTION; PULSED FIELD GEL ELECTROPHORESIS; SINGAPORE; BACTERIAL INFECTION; DRUG EFFECT; ENZYMOLOGY; GENERAL HOSPITAL; GENETICS; HUMAN; ISOLATION AND PURIFICATION; METABOLISM; MICROBIOLOGICAL EXAMINATION; MICROBIOLOGY; MOLECULAR GENETICS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

ACINETOBACTER BAUMANNII; ACINETOBACTER INFECTIONS; ANTI-BACTERIAL AGENTS; BACTERIAL PROTEINS; BETA-LACTAMASES; CARBAPENEMS; DRUG RESISTANCE, BACTERIAL; HOSPITALS, GENERAL; HUMANS; MICROBIAL SENSITIVITY TESTS; MOLECULAR SEQUENCE DATA; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SINGAPORE;

EID: 34250006926     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkl544     Document Type: Article

References (30)

1. Poirel L, Nordmann P. Carbapenem resistance in Acinetobacter baumannit. mechanisms and epidemiology. Clin Microbiol Infect 2006; 12: 826-36.
2. Brown S, Amyes S. OXA (beta)-lactamases in Acinetobacter. the story so far. J Antimicrob Chemother 2006; 57: 1-3.
3. Lee K, Lee WG, Uh Y et al. VIM- and IMP-type metallo-beta-lactamase-producing Pseudomonas spp. and Acinetobacter spp. in Korean hospitals, Emerg Infect Diseases 2003; 9: 868-71.
4. Heritier C, Poirel L, Lambert T et al. Contribution of acquired carbapenem-hydrolyzing oxacillinases to carbapenem resistance in Acinetobacter baumannii. Antimicrob Agents Chemother 2005; 49: 3198-202.
5. Brown S, Amyes SG. The sequences of seven class D beta-lactamases isolated from carbapenem-resistant Acinetobacter baumannii from four continents. Clin Microbiol Infect 2005; 11: 326-9.
6. Poirel L, Marque S, Heritier C et al. OXA-58, a novel class D beta-lactamase involved in resistance to carbapenems in Acinetobacter baumannii. Antimicrob Agents Chemother 2005; 49: 202-8.
7. National Committee for Clinical Laboratory Standards. Performance Standards for Antimicrobial Disc Susceptibility Tests - Seventh Edition Approved Standard M2-A7. NCCLS, Wayne, PA, USA, 2000.
8. Afzal-Shah M, Villar HE, Livermore DM. Biochemical characteristics of a carbapenemase from an Acinetobacter baumannii isolate collected in Buenos Aires, Argentina. J Antimicrob Chemother 1999; 43: 127-31.
9. Nordmann P, Poirel L. Emerging carbapenemases in Gram-negative aerobes. Clin Microbiol Infect 2002; 8: 321-31.
10. Chu YW, Afzal-Shah M, Houang ET et al. IMP-4, a novel metallo-beta-lactamase from nosocomial Acinetobacter spp. collected in Hong Kong between 1994 and 1998. Antimicrob Agents Chemother 2001; 45: 710-14.
11. Yan JJ, Hsueh PR, Ko WC et al. Metallo-beta-lactamases in clinical Pseudomonas isolates in Taiwan and identification of VIM-3, a novel variant of the VIM-2 enzyme. Antimicrob Agents Chemother 2001; 45: 2224-8.
12. Afzal-Shah M, Woodford N, Livermore DM. Characterization of OXA-25, OXA-26, and OXA-27, molecular class D beta-lactamases associated with carbapenem resistance in clinical isolates of Acinetobacter baumannii. Antimicrob Agents Chemother 2001; 45: 583-8.
13. Heritier C, Dubouix A, Poirel L et al. A nosocomial outbreak of Acinetobacter baumannii isolates expressing the carbapenem-hydrolysing oxacillinase OXA-58. J Antimicrob Chemother 2005; 55: 115-8.
14. Heritier C, Poirel L, Foumier PE et al. Characterization of the naturally occurring oxacillinase of Acinetobacter baumannii. Antimicrob Agents Chemother 2005; 49: 4174-9.
15. Levesque C, Piche L, Larose C et al. PCR mapping of integrons reveals several novel combinations of resistance genes. Antimicrob Agents Chemother 1995; 39: 185-91.
16. Ling ML, Ang A, Wee M et al. A nosocomial outbreak of multiresistant Acinetobacter baumannii originating from an intensive care unit. Infect Control Hosp Epidemiol 2001; 22: 48-9.
17. Senda K, Arakawa Y, Ichiyama S et al. PCR detection of metallo-beta-lactamase gene (blaIMP) in gram-negative rods resistant to broad-spectrum beta-lactams. J Clin Microbiol 1996; 34: 2909-13.
18. Paton R, Miles RS, Hood J et al. ARI-1: Beta-lactamase-mediated imipenem resistance in Acinetobacter baumannii. Int J Antimicrob Agents 1993; 2: 81-8.
19. Turton JF, Kaufmann ME, Glover J et al. Detection and typing of integrons in epidemic strains of Acinetobacter baumannii found in the United Kingdom. J Clin Microbiol 2005; 43: 3074-82.
20. Brown S, Young HK, Amyes SG. Characterisation of OXA-51, a novel class D carbapenemase found in genetically unrelated clinical strains of Acinetobacter baumannii from Argentina. Clin Microbiol Infect 2005; 11: 15-23.
21. Poumaras S, Markogiannakis A, Ikonomidis A et al. Outbreak of multiple clones of imipenem-resistant Acinetobacter baumannii isolates expressing OXA-58 carbapenemase in an intensive care unit. J Antimicrob Chemother 2006; 57: 557-61.
22. Coelho J, Woodford N, Afzal-Shah M et al. Occurrence of OXA-58-like carbapenemases in Acinetobacter spp. collected over 10 years in three continents. Antimicrob Agents Chemother 2006; 50 756-8.
23. Turton JF, Ward ME, Woodford N et al. The role of ISAba1 in expression of OXA carbapenemase genes in Acinetobacter baumannii. FEMS Microbiol Lett 2006; 258: 72-7.
24. Laraki N, Franceschini N, Rossolini GM et al. Biochemical characterization of the Pseudomonas aeruginosa 101/1477 metallo-beta-lactamase IMP-1 produced by Escherichia coli. Antimicrob Agents Chemother 1999; 43: 902-6.
25. Hawkey PM, Xiong J, Ye H et al. Occurrence of a new metallo-beta-lactamase IMP-4 carried on a conjugative plasmid in Citrobacter youngae from the People's Republic of China. FEMS Microbiol Lett 2001; 194: 53-7.
26. Peleg AY, Franklin C, Bell J et al. Emergence of IMP-4 metallo-beta-lactamase in a clinical isolate from Australia. J Antimicrob Chemother 2004; 54: 699-700.
27. Poirel L, Pham JN, Cabanne L et al. Carbapenem-hydrolysing metallo-beta-lactamases from Klebsiella pneumoniae and Escherichia coli isolated in Australia. Pathology 2004; 36 366-7.
28. Thomas L, Espedido B, Watson S et al. Forewarned is forearmed: antibiotic resistance gene surveillance in critical care. J Hosp Infect 2005; 60: 291-3.
29. IMP-4 among gram-negative pathogens in a clinical setting in Australia. Clin Infect Dis 2005; 41: 1549-56.
30. Peleg AY, Franklin C, Walters LJ et al. OXA-58 and IMP-4 carbapenem-hydrolyzing beta-lactamases in an Acinetobacter junii blood culture isolate from Australia. Antimicrob Agents Chemother 2006; 50: 399-400.